KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Con...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 25, 2024

Eiseman Jewels Celebrates Mother’s Day With Two Designer Trunk Shows • Prudential Financial empowers young changemakers with $15,000 each at Emerging Visionaries Summit • Choice Hotels International Unveils Year of Sustainability Milestones in Newly Published 2023 Environmental, Social, and Governa • National Philanthropic Trust Appoints Holly Welch Stubbing President and Chief Executive Officer • Top Tutoring Firm and Education Nonprofit Team up to Offer Free Math Tutoring for Bay Area Students • 2024 Report by Penny Finance Confirms: The Great Wealth Transfer Will Not Solve The Wealth Gap Crisis • Brigadier General James A. Ryans II to Deliver Keynote Address at National University's 2024 Commencement on May 18 in Petco Par • Thirty Madison's Nurx and Cove partner with Talkspace to expand mental health support for more than half a million women • LENSRXLAB Introduces Groundbreaking Vision Benefits Platform Catered to Diabetic Individuals • Study from Phoenix Children's Research Institute Reveals New Way to Prevent Lung Cancer from Spreading • Mercedes-Benz USA and Atlanta Falcons’ Bijan Robinson Team Up with Little Free Library to Build 175 Book-Sharing Boxes Acr • SONIC® Drive-In Celebrates Teacher Appreciation Week with Bundle of Freebies for Educators • Shoreline Equity Partners Announces Investment in Prime Meats • PINKDX LAUNCHES WITH $40 MILLION SERIES A FINANCING TO DEVELOP DIAGNOSTICS ADDRESSING UNMET MEDICAL NEEDS FOR WOMEN • BioInnovation Institute & Science announce the launch of the Translational Medicine Prize for Innovations in Women´s H • Gibson Dunn and Barrasso Usdin File Civil Rights Lawsuit to Secure Constitutional Rights of Young Woman Incarcerated for Over Si • Dickens Sanomi Academy Celebrates 10 Years of Transforming Lives, Welcomes Michael Boulos and Tiffany Trump-Boulos • Wrexham AFC Announces North American Summer Tour Dates • NTT DATA Introduces Sustainable Device-as-a-Service • Marshalls Launches First-Ever "Good Stuff Style Collective" in Partnership with Celebrity Stylists Molly Dickson, Zerina Akers a

KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference

CAMBRIDGE, Mass. & SALISBURY, England , May 31 /Businesswire/ - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7th, 2023 at 2:00 p.m. ET in New York, NY.

A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be available on KalVista’s website for 30 days following the presentations.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and is enrolling the Phase 3 KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.

For more information about KalVista, please visit www.kalvista.com.

For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT trial, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2022, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.